

Your Peripheral Vision[®]

Disclaimers

Forward Looking Statements

This presentation contains certain forward-looking statements, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that involve risks and uncertainties. Actual results and events may differ significantly from results and events discussed in forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, those discussed in "Risk Factors" in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. We undertake no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made.

Non-GAAP Financial Measures

This presentation contains non-GAAP financial measures. Non-GAAP financial measures are not prepared in accordance with generally accepted accounting principles and may not be comparable to similar non-GAAP financial measures used by other companies. The most directly comparable financial measures calculated in accordance with GAAP and a reconciliation of GAAP to non-GAAP financial measures are provided at the end of this presentation.

<u>Other</u>

Unless otherwise specified, all information contained herein is provided as of September 30, 2019, except that all management guidance is as of October 23, 2019. This presentation is not a reaffirmation of management guidance, which is referenced herein for convenience only.

LMAT Investment Highlights


- \$117.2mm \$118.0mm sales in 2019*
 - +11% reported, +7% organic⁺
- \$21.9mm \$22.4mm operating income in 2019*
 - -22%⁺, +7% adjusted^{**}
- 19% operating margin⁺
- \$0.88- \$0.90 earnings per diluted share in 2019*
 - -22%⁺, +7% adjusted^{**}
- 109 sales reps
- Acquisition and R&D strategy
- \$44.9mm cash & short term investments, no debt
- Dividend payer
- \$10mm share repurchase program authorized

^{*} Management guidance 10/23/19

⁺ Percentages are based on midpoint of guidance range

^{**} Adjusted operating income & EPS growth rates exclude 1X gains & losses from acquisitions, divestitures, & restructuring (net of tax)

Top & Bottom Line Growth



* 2019 amount is midpoint of 10/23/19 guidance range, and CAGR is based on 2014 to 2019 period

** 1X gains are from acquisition and divestiture transactions

Overview of LeMaitre's Strategy


Focused Call Point: Vascular Surgeon

Niche Markets

Growth Platform

- Sales force expansion
- R&D introductions
- Acquisitions

Focused Call Point: Vascular Surgeon



Source: Management surveys of LeMaitre field sales personnel

Vascular Surgeons*:


- 15,000 Worldwide
- >50% use LeMaitre products

LeMaitre Hospital Customers:

- 4,500 Worldwide
- Average purchases/hospital: ~\$22,000


* Source: Management estimate

\$900mm TAM Across LeMaitre's 15 Markets




- All 15 Markets Are Niche (<\$200mm)
- #1 or #2 Share in 12 of 15 Markets
- TAM is <20% of \$5b
 Peripheral Vascular Market

Diversified Sales Bag




These product lines represented approximately 85% of total sales in Q3 2019

Sales Mix by Product Category




9

Worldwide Sales Reach: 109 Sales Reps & 11 Offices



~5 Sales Reps Added per Year



Regulatory Approvals: Direct Sales Channel

	Ame	ericas	EMEA		Asia Pa	cific Rim	
Product Lines	US	Canada	Europe	Australia	NZ	Japan	China
LeMaitre Valvulotome							
VascuTape Radiopaque Tape							
Embolectomy Catheters: SL OTW NovaSil							
Applied Catheters: Syntel Python Latis							
Occlusion Catheters: Aortic PIOC Small DPC							
Carotid Shunts: Pruitt F3 F3-S Flexcel							
AnastoClip: AC GC							
Elongated AnastoClip: AC GC							
EndoRE Devices: MollRing MultiTASC							
AlboGraft AlboSure Polyester Graft Patch							
Cardial Surgical Glue							
XenoSure XenoSure Plus DuraSure							Clin. Trial
LifeSpan ePTFE Graft							
LeverEdge Contrast Injector							
TRIVEX System							
Omniflow II Biosynthetic Graft							
Angioscope							
ProCol Biologic Graft							
RestoreFlow Allografts							
% of WW Sales That Approved Products Represent*	94%	97%	89%	85%	90%	54%	23%

APPROVED

SUBMITTED

Regulatory Approvals: Distributor Sales Channel

	Americas		EN	/IEA		Asia Pacific Rim			
Product Lines	Brazil	S. Africa	Turkey	Saudi	Russia	Vietnam	Thailand	Korea	Taiwan
LeMaitre Valvulotome									
VascuTape Radiopaque Tape									
Embolectomy Catheters: SL OTW NovaSil									
Applied Catheters: Syntel Python Latis									
Occlusion Catheters: Aortic PIOC Small DPC									
Carotid Shunts: Pruitt F3 F3-S Flexcel									
AnastoClip: AC GC									
Elongated AnastoClip: AC GC									
EndoRE Devices: MollRing MultiTASC									
AlboGraft AlboSure Polyester Graft Patch									
Cardial Surgical Glue									
XenoSure XenoSure Plus DuraSure									
LifeSpan ePTFE Graft									
LeverEdge Contrast Injector									
TRIVEX System									
Omniflow II Biosynthetic Graft									
Angioscope									
ProCol Biologic Graft									
RestoreFlow Allografts									
% of WW Sales That Approved Products Represent*	[•] 74%	81%	84%	76%	49%	75%	76%	72%	31%

APPROVED



R&D Launch Record (13-6-2)

13 WINS† Product Year 1.8mm Valvulotome 2001 Novasil Latex-Free Embo. 2002 Catheter **Reddick Scoop Tip** 2003 Cholangiogram Catheter* **Flexcel Carotid Shunt** 2004 **Distal Perfusion Catheter** 2004 5F Plus O-T-W Embo 2004 Catheter 2007 Pruitt F3 Carotid Shunt 2010 AnastoClip GC 2013 **AlboSure Polyester Patch** 2013 1.5mm Valvulotome 2014 HYDRO Valvulotome 2016 15cm AnastoClip AC 2018 15cm AnastoClip GC

YearProduct2004InvisiGrip Vein Stripper*2007TT Delivery System*2008TAA Top Stent*2011O-T-W Valvulotome2011The UnBalloon*2013MultiTASC

6 LOSSES

<u>2 TBD</u>

Product
XenoSure Plus
DuraSure

Legend


SKU Expansion

Next Generation

New

 Management determination of win vs. loss vs. TBD incorporates factors including but not limited to: sales, sales growth, profitability, and return on investment
 * Discontinued/Divested

23 Acquisitions in 22 years



Acquisition of CardioCel & VascuCel Patches

- Acquired from Admedus October 11, 2019
- Cardiac & vascular biologic patches
- 9/30/19 YTD Annualized Sales: \$7.1mm
- Consideration:
 - Cash: \$15.5mm (2.2X sales)
 - Potential Earnouts: \$7.8mm
 - Potential Total: \$23.3mm (3.3X sales)
- Acquisition Rationale:
 - Generation 2.0 technology: anti-calcification & decellularized
 - Strengthens LeMaitre's presence in biologic patch market
- Production to be relocated from Perth, Australia 1-3 years post-closing



Acquisitions Record (13-5-5)

Embolectomy

Catheters

Weighted Avg. Multiple Paid

4.2x

2.1x

2018


	WIN (13)†			LOSS (5)			Tie or TBD (5)	
Year	Product	Multiple of Sales Paid	Year	Product	Multiple of Sales Paid	Year	Product	Multiple of Sales Paid
1998	VascuTape	0.3x	2003	Dialysis Grafts*	9.5x	2013	TRIVEX	1.1x
1999	Embolectomy	0.9x	2005	Stent Grafts*	2.3x	2016	ProCol	2.1x
	Catheters		2007	UnBalloon*	N/A		Polyester Grafts,	
2001	Carotid Shunt, Embo. Catheters	1.1x	2007	AlboGraft	2.8x	2018	Chevalier Valvulotome,	0.7x
2004	AnastoClip	0.6x	2007	EndoRE	1.7x		Surgical Glue	
2007	LeverEdge	1.8x	Weight	ed Avg. Multiple Paid	2.7x	2019	Tru-Incise (US)	5.1x
2010	LifeSpan	2.3x				2019	CardioCel/ VascuCel**	2.2x-3.3x
2012	XenoSure	1.0x				Weight	ed Avg. Multiple Paid	2.2x
2013	Carotid Shunt, Embo Catheters	1.9x						
2014	Omniflow II	2.5x						
2014	Angioscope	1.2x						
2015	Tru-Incise (OUS)	5.6x	14/	eighted Average M	ultinle of s	ales of	all 23 Acquisitions:	2 2x
2016	Restore Flow Allografts	3.8x						2.27

⁺ Management win/loss/TBD classification incorporates factors including but not limited to: sales growth, gross margin, operating contribution, and return on investment

* Discontinued/Divested

** CardioCel/VascuCel multiple is a range given potential earnout payments. TBD & overall weighted averages include midpoint of CardioCel/VascuCel range


Financials: High-Quality Sales



† Q3 2019 Sales

**Approximate, in LeMaitre Direct Territories


19% Operating Margin




* Excludes 1X gains from acquisitions and divestitures


** Amount based on midpoint of 10/23/19 guidance range

EBITDA Funds Dividends & Acquisitions






Return on Invested Capital*



*Calculation: Tax-Affected Operating Income for Trailing-12-Month Period / (Equity - (Cash & Short-Term Investments))

Liquidity & Stock Ownership Trends



** Beneficial ownership excluding options as percentage of 19,979,928 shares outstanding as of 9/30/19

21

Investors, Analysts, & Conferences

Inside Shareholders holding >1%*						
George W. LeMaitre		15.5%				
Top 25 Institutional Shareholders**						
BlackRock Fund	San Francisco	12.1%				
Conestoga	Philadelphia	8.7%				
Vanguard	Philadelphia	6.9%				
Dimensional	Austin	5.1%				
Janus	Denver	3.4%				
State Street	Boston	3.1%				
Ranger	Dallas	3.1%				
Copeland	Philadelphia	2.7%				
Columbia Threadneedle	Boston	1.6%				
AWM (Special Situations)	New York	1.6%				
Summit Creek	Minneapolis	1.5%				
ТНВ	Norwalk	1.4%				
Geode	Boston	1.3%				
Wasatch	Salt Lake City	1.2%				
Bahl & Gaynor	Cincinnati	1.2%				
Northern Trust	Chicago	1.1%				
Mellon	Boston	0.9%				
Kennedy	St. Louis	0.8%				
Amundi	Paris	0.8%				
Wells	San Francisco	0.8%				
Rhumbline	Boston	0.8%				
Principal Global	Des Moines	0.7%				
Morgan Stanley	New York	0.7%				
Argenta	Luxembourg	0.7%				
GW&K	Boston	0.6%				

 \ast Beneficial ownership excluding options as percentage of 19,979,928 shares outstanding as of 9/30/19

** Institutional ownership based on 13Fs for period ended 9/30/19

Analyst Coverage	
Barrington Research	Michael Petusky
Canaccord Genuity	Jason Mills
First Analysis	Joseph Munda
Lake Street Capital	Brooks O'Neil
Roth	Scott Henry
Sidoti	James Sidoti
Stifel	Rick Wise

Upcoming Investor Conferences							
Stifel	NYC	Nov 20					
Canaccord	NYC	Nov 21					
Needham	NYC	Jan 14 – 15					

Common Shares (Weighted Average)				
Outstanding	20.0mm			
Fully Diluted	20.4mm			

Quarterly Midpoint of Guidance Achievement Record							
Sales Guidance	27 of 39 Quarters	(69%)					
Operating Income Guidance	28 of 39 Quarters	(72%)					
Earnings Per Share Guidance	8 of 10 Quarters	(80%)					

GAAP to Non-GAAP Financial Measure Reconciliation

econciliation between GAAP and Non-GAAP projected sales For the year ending December 31, 2019	5			
Net sales per guidance (midpoint)	\$	117,611		
Impact of currency exchange rate fluctuations		2,213		
Net impact of acquisitions excluding currency		(7,701)		
Adjusted projected net sales			\$ 112,123	
For the year ended December 31, 2018				
Net sales as reported	\$	105,568		
Net impact of divestitures excluding currency		(787)		
Adjusted net sales			\$ 104,781	
Adjusted projected net sales increase for the year endin	g December 31, 2019		\$ 7,342	7%

Reconciliation between GAAP and Non-GAAP projected operating income:				
For the year ending December 31, 2019	e	00 400		
Operating income per guidance (midpoint)	\$	22,132		
Add back restructuring charge		147		
Adjusted projected operating income			\$ 22,279	
For the year ended December 31, 2018				
Operating income as reported	\$	28,209		
Impact of gains on acquisitions and divestitures		(7,474)		
Adjusted operating income			\$ 20,735	
Adjusted projected operating income increase for the year ending				
December 31, 2019			\$ 1,544	7%

GAAP to Non-GAAP Financial Measure Reconciliation

Reconciliation between GAAP and Non-GAAP projected earnings per share	e:			
For the year ending December 31, 2019				
Earnings per share per guidance (midpoint)	\$	0.89		
Add back earnings per share from restructuring charge, net of tax	\$	0.00		
Adjusted projected earnings per share			\$ 0.89	
For the year ended December 31, 2018				
Earnings per share as reported	\$	1.13		
Less earnings per share from gains on acquisitions and				
divestitures, net of tax	\$	(0.30)		
Adjusted earnings per share			\$ 0.83	
Adjusted projected earnings per share increase for the year				
ending December 31, 2019			\$ 0.06	7%

Reconciliation between GAAP and Non-GAAP EBITDA:	2015	2016	2017	2018	9/30/19 YTD
Net income as reported	\$7,758	\$10,590	\$17,177	\$22,943	\$13,321
Interest (income) expense, net	(13)	(67)	(158)	(629)	(574)
Amortization and depreciation expense	3,394	3,591	4,055	4,324	3,975
Provision for income taxes	3,666	5,652	3,929	5,501	3,170
EBITDA	\$14,805	\$19,766	\$25,003	\$32,139	\$19,892



Your Peripheral Vision[®]

Thank You